Clinical Trial Update: GSK1349572 Drug Interaction Study With Protease Inhibitors [Phase 1]

View source ↗

Summary

A Phase 1 drug interaction study evaluating dolutegravir (GSK1349572) with protease inhibitors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tivicay (dolutegravir)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus | Phase 1 | Status: COMPLETED